Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

ts receiving OGX-011 plus docetaxel retreatment was 15.8 months, whereas the median survival duration for the randomized 22 patients receiving OGX-011 plus mitoxantrone arm was 11.4 months, based on a median follow-up of 26 months. An amendment to the study provided for an additional 25 patients to be treated with OGX-011 and docetaxel retreatment as second-line chemotherapy. The median survival duration for all 45 patients (i.e., the 20 randomized plus the 25 enrolled after randomization) receiving OGX-011 plus docetaxel retreatment is 13.0 months, based on a median follow-up of 18 months. For comparison, results were published for patients who participated in the key registration study comparing first-line docetaxel to mitoxantrone in metastatic CRPC, referred to as the TAX 327 Study, and who later received second-line chemotherapy. The median survival duration for these patients treated with either docetaxel or mitoxantrone as second-line chemotherapy was approximately 10 months. A retrospective study from the British Columbia Cancer Agency reported a median survival duration of 9.6 months for patients who were retreated with docetaxel as second-line chemotherapy after receiving and responding to docetaxel as first- line chemotherapy. - Non-Small Cell Lung Cancer Potential Survival Advantage - longer than expected survival duration was observed when adding OGX-011 to first- line gemcitabine and a platinum-containing chemotherapy when compared to reported survival durations in prior published studies from randomized phase 3 trials evaluating first-line gemcitabine and a platinum-containing chemotherapy in patients with non-small cell lung cancer ("NSCLC"). At two years, 30% of patients who had received OGX- 011 with first-lin
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Streetsboro, Ohio (PRWEB) April 16, 2015 ... Safety Index, overexertion involving an outside source was ... injuries. This includes injuries related to lifting, pushing, ... $15.1 billion in direct costs. The David Round ... Round is committed to working hard to develop ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is ... newest office in Charlottetown , PEI.  ... Prince Edward Island ADAPT Council for the commercialization of ... forward to working with PEI ADAPT.  They have been ... more than a decade," explains Dave Smardon , ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... 20, 2010) -- Recently, academic debate has been swirling ... the most ubiquitous of phenomena, including photosynthesis, the process ... particular, physicists have suggested that entanglement (the quantum interconnection ... atoms that are separated in physical space) could be ...
... ,, CHANTILLY, Va. , Aug. 6 ... as director of Chemical-Biological Defense Programs.  In this role, Chotani will lead ... U.S. Army and the Office of the Secretary of Defense, as well ... Health and the Centers for Disease Control. , ...
... Thursday, August 5, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA and VANCOUVER , Aug. 5 /PRNewswire-FirstCall/ - ... unaudited financial results for the three and six months ended June 30, 2010 and ... , , ...
Cached Biology Technology:TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 2TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 3OncoGenex Reports Second Quarter Financial Results 2OncoGenex Reports Second Quarter Financial Results 3OncoGenex Reports Second Quarter Financial Results 4OncoGenex Reports Second Quarter Financial Results 5OncoGenex Reports Second Quarter Financial Results 6OncoGenex Reports Second Quarter Financial Results 7OncoGenex Reports Second Quarter Financial Results 8OncoGenex Reports Second Quarter Financial Results 9
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... genes are especially challenging because they combine many ... of non-coding elements (introns). During processing, introns are ... a template for proteins called messenger RNA (mRNA). ... of a functional protein or, worse, produce an ...
... Institute of Dental and Craniofacial Research (NIDCR), part of ... new piece to the puzzle of how tumor cells ... abnormal growth, a well-known process called angiogenesis. , As ... Cell, the scientists found that in addition to the ...
... cancer that is based on infection with a specially designed ... has shown promise in clinical trials. Now, new research suggests ... as well. The study, published in the July issue of ... to viral therapy after they have been incubated at an ...
Cached Biology News:Carnegie Mellon University research reveals how cells process large genes 2Carnegie Mellon University research reveals how cells process large genes 3New lead reported in tumor angiogenesis 2New lead reported in tumor angiogenesis 3Elevated temperature enhances success of viral cancer therapy 2
HistoScan AP Universal Goat Kit...
4',6-Diamidino-2-phenylindole dihydrochloride...
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Biology Products: